Browsing Tag
Brepocitinib
2 posts
Roivant’s LISRAYA wins FDA approval as $26bn biotech enters commercial autoimmune era
Roivant has secured FDA approval for LISRAYA in adults with dermatomyositis, converting brepocitinib into a commercial product while retaining multiple late-stage opportunities in other autoimmune diseases.
Pfizer-backed Priovant wins FDA priority review for brepocitinib in dermatomyositis
FDA grants priority review to Priovant's brepocitinib NDA for dermatomyositis with a Q3 2026 PDUFA date. Read what this means for Roivant, Pfizer, and the autoimmune market.